{"id":58026,"date":"2026-02-26T16:28:01","date_gmt":"2026-02-26T08:28:01","guid":{"rendered":"https:\/\/flcube.com\/?p=58026"},"modified":"2026-02-26T16:28:02","modified_gmt":"2026-02-26T08:28:02","slug":"steincares-partners-with-shilpa-biologicals-on-latin-america-biosimilar-deal-regional-commercialization-agreement","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58026","title":{"rendered":"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement"},"content":{"rendered":"\n<p><strong>SteinCares<\/strong>, a <strong>leading specialty healthcare company in Latin America<\/strong>, and <strong>Shilpa Biologicals Pvt. Ltd. (SBPL)<\/strong>, a <strong>fully integrated biopharmaceutical subsidiary<\/strong> of <strong>Shilpa Medicare Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/530549:BOM\">BOM:\u202f530549<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/SHILPAMED:NSE\">NSE:\u202fSHILPAMED<\/a>)<\/strong>, announced a <strong>strategic licensing agreement<\/strong> to <strong>commercialize a biosimilar across Latin America<\/strong>. The partnership combines SBPL&#8217;s <strong>biologics development and manufacturing expertise<\/strong> with SteinCares&#8217; <strong>integrated regional commercial platform<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner 1<\/strong><\/td><td>SteinCares (Latin America specialty healthcare)<\/td><\/tr><tr><td><strong>Partner 2<\/strong><\/td><td>Shilpa Biologicals Pvt. Ltd. (SBPL), subsidiary of Shilpa Medicare (BOM:\u202f530549, NSE:\u202fSHILPAMED)<\/td><\/tr><tr><td><strong>Collaboration Type<\/strong><\/td><td>Strategic licensing agreement<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Biosimilar (specific molecule undisclosed)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Latin America (exclusive)<\/td><\/tr><tr><td><strong>SteinCares Rights<\/strong><\/td><td>Registration, commercialization, distribution<\/td><\/tr><tr><td><strong>SBPL Responsibilities<\/strong><\/td><td>Product development + commercial manufacturing<\/td><\/tr><tr><td><strong>Manufacturing Site<\/strong><\/td><td>Dharwad, India facility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure\">Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Function<\/th><th>Responsibility<\/th><th>Location<\/th><\/tr><\/thead><tbody><tr><td><strong>Development<\/strong><\/td><td>SBPL<\/td><td>India<\/td><\/tr><tr><td><strong>Manufacturing<\/strong><\/td><td>SBPL \u2013 Dharwad facility<\/td><td>India<\/td><\/tr><tr><td><strong>Regulatory Registration<\/strong><\/td><td>SteinCares<\/td><td>Latin America<\/td><\/tr><tr><td><strong>Commercialization<\/strong><\/td><td>SteinCares<\/td><td>Latin America<\/td><\/tr><tr><td><strong>Distribution<\/strong><\/td><td>SteinCares<\/td><td>Latin America<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Latin America Market Access:<\/strong> SteinCares&#8217; <strong>established regional infrastructure<\/strong> provides SBPL with immediate market entry across <strong>diverse regulatory environments<\/strong> (Brazil, Mexico, Argentina, Colombia, etc.) without building proprietary commercial teams.<\/li>\n\n\n\n<li><strong>Manufacturing Cost Advantage:<\/strong> SBPL&#8217;s <strong>Indian manufacturing base<\/strong> offers <strong>cost\u2011competitive biosimilar production<\/strong>, critical for price\u2011sensitive Latin American healthcare systems and government procurement.<\/li>\n\n\n\n<li><strong>Risk Sharing:<\/strong> The <strong>development\u2011manufacturing \/ commercialization split<\/strong> aligns incentives\u2014SBPL ensures product quality and supply; SteinCares drives market penetration and revenue generation.<\/li>\n\n\n\n<li><strong>Biosimilar Growth Trend:<\/strong> Latin America represents an <strong>emerging biosimilar market<\/strong> with increasing regulatory harmonization and payer acceptance; early partnerships secure first\u2011mover positioning.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Latin America Biosimilar Market<\/strong><\/td><td>Projected double\u2011digit growth driven by healthcare cost containment and patent expiries of major biologics<\/td><\/tr><tr><td><strong>SteinCares Positioning<\/strong><\/td><td>Leading specialty pharma platform with established relationships across hospitals, pharmacies, and government channels<\/td><\/tr><tr><td><strong>Shilpa Medicare Expansion<\/strong><\/td><td>Biosimilar partnership extends SBPL&#8217;s global footprint beyond India and established markets into high\u2011growth Latin America<\/td><\/tr><tr><td><strong>Regulatory Landscape<\/strong><\/td><td>ANVISA (Brazil), COFEPRIS (Mexico) increasing biosimilar approval pathways; SteinCares&#8217; regulatory expertise de\u2011risks market entry<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding product registration timelines, commercial launch dates, and market penetration expectations. Actual results may differ due to risks including regulatory approval delays, competitive biosimilar launches, and pricing pressure in Latin American markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL),&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[43,4628,4629,4627,2789],"class_list":["post-58026","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biosimilars","tag-bom-530549","tag-nse-shilpamed","tag-shilpa-biologicals","tag-steincares"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM:\u202f530549, NSE:\u202fSHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL&#039;s biologics development and manufacturing expertise with SteinCares&#039; integrated regional commercial platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58026\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement\" \/>\n<meta property=\"og:description\" content=\"SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM:\u202f530549, NSE:\u202fSHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL&#039;s biologics development and manufacturing expertise with SteinCares&#039; integrated regional commercial platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58026\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-26T08:28:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-26T08:28:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58026#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58026\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement\",\"datePublished\":\"2026-02-26T08:28:01+00:00\",\"dateModified\":\"2026-02-26T08:28:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58026\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biosimilars\",\"BOM:\u202f530549\",\"NSE:\u202fSHILPAMED\",\"Shilpa Biologicals\",\"SteinCares\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58026#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58026\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58026\",\"name\":\"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-26T08:28:01+00:00\",\"dateModified\":\"2026-02-26T08:28:02+00:00\",\"description\":\"SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM:\u202f530549, NSE:\u202fSHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL's biologics development and manufacturing expertise with SteinCares' integrated regional commercial platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58026#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58026\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58026#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement - Insight, China&#039;s Pharmaceutical Industry","description":"SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM:\u202f530549, NSE:\u202fSHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL's biologics development and manufacturing expertise with SteinCares' integrated regional commercial platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58026","og_locale":"en_US","og_type":"article","og_title":"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement","og_description":"SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM:\u202f530549, NSE:\u202fSHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL's biologics development and manufacturing expertise with SteinCares' integrated regional commercial platform.","og_url":"https:\/\/flcube.com\/?p=58026","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-26T08:28:01+00:00","article_modified_time":"2026-02-26T08:28:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58026#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58026"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement","datePublished":"2026-02-26T08:28:01+00:00","dateModified":"2026-02-26T08:28:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58026"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biosimilars","BOM:\u202f530549","NSE:\u202fSHILPAMED","Shilpa Biologicals","SteinCares"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58026#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58026","url":"https:\/\/flcube.com\/?p=58026","name":"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-26T08:28:01+00:00","dateModified":"2026-02-26T08:28:02+00:00","description":"SteinCares, a leading specialty healthcare company in Latin America, and Shilpa Biologicals Pvt. Ltd. (SBPL), a fully integrated biopharmaceutical subsidiary of Shilpa Medicare Limited (BOM:\u202f530549, NSE:\u202fSHILPAMED), announced a strategic licensing agreement to commercialize a biosimilar across Latin America. The partnership combines SBPL's biologics development and manufacturing expertise with SteinCares' integrated regional commercial platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58026#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58026"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58026#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal \u2013 Regional Commercialization Agreement"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58026"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58026\/revisions"}],"predecessor-version":[{"id":58028,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58026\/revisions\/58028"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}